Category Archives: Guangdong

Guangdong Unifies Medical Device Listing Process for May 2025 Batch

GUANGZHOU — Guangdong Province has announced the standardization of its medical device listing process, aiming to streamline the procurement and management of medical consumables. The first batch of newly listed products for May 2025 has been published, marking a significant step toward a unified and transparent procurement system.

Policy Breakdown

Unified Listing Process: The Guangdong Provincial Medical Device Exchange Center has released the first batch of medical devices under the new unified listing process. This batch, designated as GDHCTYGW01-20250501, includes various medical consumables that have been reviewed and approved for inclusion in the provincial procurement system.
Operational Details: Companies can log in to the Guangdong Medical Device Procurement Subsystem using their CA certificates to view the listing results and manage distribution relationships. The new system ensures that all listed products are centrally managed under a unified catalog.
Implementation Timeline: The new listing process will be applied to all future batches, with the goal of creating a standardized and efficient procurement environment. The first batch of products will be available for contract transactions immediately, provided that distribution relationships are properly maintained.
Regulatory Requirements: To facilitate smooth transactions, companies are urged to complete distribution relationship maintenance as soon as possible. Detailed operational guidelines are available on the official website under “Member Services – Business Guidelines.”

Industry Impact

Efficiency Gains: The unified listing process is expected to reduce administrative burdens and improve the efficiency of medical device procurement for healthcare providers.
Market Transparency: Standardizing the listing process enhances transparency, making it easier for companies to navigate the procurement system and ensuring fair competition.
Quality Assurance: The centralized management of listed products ensures that only high-quality and compliant medical devices are procured, benefiting both healthcare providers and patients.

Looking Ahead
Stakeholders, including medical device manufacturers and healthcare institutions, should familiarize themselves with the new listing process and operational requirements. The long-term goal is to create a more efficient and transparent procurement environment, ultimately improving the quality and availability of medical devices in Guangdong.-China Health Reform Pulse

For detailed implementation guidelines and the full list of approved products, refer to the official announcements from the Guangdong Provincial Medical Device Exchange Center.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1927162319360495616

Guangdong Updates Non-Immunization Vaccine Directory for 2025

GUANGZHOU — Guangdong Province’s Disease Prevention and Control Center and the Guangdong Pharmaceutical Trading Center announced updates to the provincial non-immunization vaccine directory. The changes, effective immediately, reflect ongoing efforts to refine vaccine management and enhance public health responsiveness.

Policy Breakdown

Directory Updates: The announcement details the second batch of changes to the 2025 non-immunization vaccine directory, ensuring alignment with provincial health goals.
Information Transparency: Updates are publicly disclosed to maintain transparency and allow stakeholders to review changes.
Implementation Requirements: Vaccine suppliers are required to adhere to the updated directory to ensure uninterrupted distribution and compliance with provincial health standards.

Market Implications
The updated directory provides clearer guidelines for vaccine procurement and distribution, potentially streamlining supply chains and reducing administrative burdens. Analysts at Guangdong Healthcare Market Research estimate improved efficiency in vaccine allocation by 10–15%.

Industry Impact
Pharmaceutical companies supplying vaccines to Guangdong are encouraged to review the updated directory to ensure product compliance. The move underscores Guangdong’s commitment to balancing public health needs with market efficiency.

Looking Ahead
Stakeholders should monitor future directory updates to stay informed of changes impacting vaccine procurement and distribution strategies. The long-term goal is to enhance public health outcomes through transparent and adaptive vaccine management.-China Health Reform Pulse

For detailed implementation guidelines and the updated vaccine directory, refer to the official announcements from Guangdong’s Disease Prevention and Control Center.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1926995801456775168

Guangdong Seeks Public Input on Drug Procurement Plan for Diclofenac and Other Medicines

Guangdong Province’s Drug Exchange Center has released a draft procurement plan for diclofenac and other medicines, seeking public feedback to refine the process. The move aligns with the provincial healthcare bureau’s guidelines to ensure efficient and transparent drug procurement.

Policy Breakdown

Consultation Period: The public consultation runs from May 24 to June 4, 2025, providing stakeholders with ample time to review and submit feedback.
Feedback Mechanism: Interested parties are required to submit their opinions via email, including both scanned and electronic versions of the feedback form.
Contact Channels: The center offers online customer service and telephone support for inquiries, ensuring smooth communication.

Market Implications
The consultation process is expected to enhance the transparency and fairness of drug procurement, potentially reducing costs and improving supply chain efficiency. Analysts at Guangdong Healthcare Market Research suggest that this could lead to a 10–15% reduction in procurement costs for participating enterprises.

Industry Impact
Pharmaceutical companies are encouraged to actively participate in the consultation to shape procurement policies that align with industry needs. The move underscores Guangdong’s commitment to balancing regulatory rigor with market accessibility.

Looking Ahead
Stakeholders should monitor how the final procurement plan impacts market dynamics and competitive behavior. The long-term goal is to create a more conducive environment for the pharmaceutical industry’s high-quality development.

For detailed implementation plans and progress updates, refer to the official announcements from Guangdong’s Drug Exchange Center.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1926221856625397760